se of the VExUS Ultrasound Score to quantify venous congestion in patients with acute decompensated heart failure (VExUS-HF)

Recruiting

Conditions: I51
Complications and ill-defined descriptions of heart disease

Registration Number: DRKS00031505

Lead Sponsor: Medizinische Hochschule Brandenburg Theodor Fontane

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

adult patients with AKD hospitalised with at least one clinical sign of volume overload (oedema, ascitis, pleural effusion), BNP > 250 pg/ml or NT-proBNP > 1000 pg/ml in routine admission laboratory, written informed consent

Exclusion Criteria

Pre-diagnosed liver cirrhosis Child-Pugh C, exclusion by examiner if sonographic image acquisition is impossible due to anatomical conditions, pre-existing dialysis requirement

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the proportion of patients with improvement in VExUS classification compared to clinical recompensation success (defined as: Weight loss, decrease in NT-pro-BNP, decrease in NYHA classification, bioimpedance measurements).

Secondary Outcome Measures

Name	Time	Method
Proportion of patients with acute kidney injury (AKI) during the inpatient stay depending on their VExUS score as well as changes in biomarker concentrations and bioimpedance measurements depending on the VExUS score.<br>Inter- and intra-rater reliability of different ultrasound examiners within the study protocol. Concordance of diuretic use and recommended medication adjustment at hospital discharge in patients' outpatient medical care. Proportion of patients with MACE during the course of the study (3 months follow-up).